Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13222MR)

This product GTTS-WQ13222MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF9 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001561.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3604
UniProt ID Q07011
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13222MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9479MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ2879MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-761
GTTS-WQ15402MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TSR-022
GTTS-WQ11026MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MCLA-117
GTTS-WQ11225MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI3902
GTTS-WQ14578MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aCD1919
GTTS-WQ4613MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ9464MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IPH4102
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW